BOSTON, MA, CORE Biomedicine, a biotechnology company pioneering lineage-based precision oncology therapeutics, today announced the completion of a $21 million Series A financing.
Continue Reading
Sign up for FREE to read the full article and access 156K+ alternative investment headlines.